Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,720,768
  • Shares Outstanding, K 155,032
  • Annual Sales, $ 0 K
  • Annual Income, $ -259,580 K
  • 60-Month Beta 0.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.23
Trade IOVA with:

Options Overview

Details
  • Implied Volatility 92.87%
  • Historical Volatility 61.87%
  • IV Percentile 84%
  • IV Rank 54.89%
  • IV High 122.38% on 05/19/21
  • IV Low 56.95% on 01/19/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 747
  • Volume Avg (30-Day) 2,462
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 11,642
  • Open Int (30-Day) 21,283

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.52
  • Number of Estimates 7
  • High Estimate -0.48
  • Low Estimate -0.55
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.39 +14.94%
on 08/23/21
25.48 -3.51%
on 09/17/21
+3.41 (+16.13%)
since 08/20/21
3-Month
20.19 +21.77%
on 08/20/21
28.00 -12.20%
on 06/30/21
-0.25 (-0.99%)
since 06/21/21
52-Week
15.88 +54.82%
on 05/19/21
54.21 -54.65%
on 01/15/21
-9.41 (-27.67%)
since 09/21/20

Most Recent Stories

More News
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

GSK : 39.04 (+0.49%)
MRK : 71.95 (+0.03%)
HOOK : 6.75 (+3.05%)
IOVA : 24.54 (+2.25%)
Implied Volatility Surging for Iovance (IOVA) Stock Options

Investors need to pay close attention to Iovance (IOVA) stock based on the movements in the options market lately.

IOVA : 24.54 (+2.25%)
Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus

Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.

MRK : 71.95 (+0.03%)
RGEN : 314.15 (+2.65%)
CLLS : 13.62 (+0.89%)
IOVA : 24.54 (+2.25%)
Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte,...

IOVA : 24.54 (+2.25%)
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August...

IOVA : 24.54 (+2.25%)
TIL-based Therapies Market by Target Indications, Key Players and Key Geographies - Global Forecast 2021-2030

Reportlinker.com announces the release of the report "TIL-based Therapies Market by Target Indications, Key Players and Key Geographies - Global Forecast 2021-2030" - https://www.reportlinker.com/p06103101/?utm_source=GNW...

IOVA : 24.54 (+2.25%)
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy

Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.

BMY : 60.43 (-0.12%)
MRK : 71.95 (+0.03%)
IOVA : 24.54 (+2.25%)
BNTX : 344.70 (+1.68%)
Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio...

IOVA : 24.54 (+2.25%)
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy

IOVA : 24.54 (+2.25%)
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically...

FSNN : 0.0580 (-19.44%)
BMEA : 10.25 (-0.97%)
EIDX : 122.21 (-4.85%)
BBIO : 49.92 (+1.42%)
IOVA : 24.54 (+2.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

3rd Resistance Point 25.38
2nd Resistance Point 24.95
1st Resistance Point 24.47
Last Price 24.54
1st Support Level 23.56
2nd Support Level 23.13
3rd Support Level 22.65

See More

52-Week High 54.21
Fibonacci 61.8% 39.57
Fibonacci 50% 35.04
Fibonacci 38.2% 30.52
Last Price 24.54
52-Week Low 15.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar